{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:24:06Z","timestamp":1783347846503,"version":"3.54.6"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,6]]},"DOI":"10.7759\/cureus.112135","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:28:58Z","timestamp":1783344538000},"source":"Crossref","is-referenced-by-count":0,"title":["From Weight Loss to Organ-Specific Disease Modification: A Narrative Review of Incretin-Based Therapies in Obesity-Related Cardiometabolic Disease, Chronic Kidney Disease, Metabolic Dysfunction-Associated Steatohepatitis, and Obstructive Sleep Apnoea"],"prefix":"10.7759","author":[{"given":"Devarsh","family":"Joshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino F","year":"2025","unstructured":"Rubino F, Cummings DE, Eckel RH, et al.. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025, 13:221-62. 10.1016\/S2213-8587(24)00316-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker DJ","year":"2022","unstructured":"Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022, 57:101351. 10.1016\/j.molmet.2021.101351","journal-title":"Mol Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst JJ","year":"2007","unstructured":"Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007, 87:1409-39. 10.1152\/physrev.00034.2006","journal-title":"Physiol Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck MA","year":"2022","unstructured":"Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022, 21:169. 10.1186\/s12933-022-01604-7","journal-title":"Cardiovasc Diabetol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding JP","year":"2022","unstructured":"Wilding JP, Batterham RL, Davies M, et al.. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022, 24:1553-64. 10.1111\/dom.14725","journal-title":"Diabetes Obes Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne LJ","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, et al.. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024, 331:38-48. 10.1001\/jama.2023.24945","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016, 375:311-22. 10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomized trials","volume":"9","author":"Sattar N","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, et al.. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomized trials. Lancet Diabetes Endocrinol. 2021, 9:653-62. 10.1016\/S2213-8587(21)00203-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff AM","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023, 389:2221-32. 10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod MN","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al.. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023, 389:1069-84. 10.1056\/NEJMoa2306963","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod MN","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, et al.. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024, 390:1394-407. 10.1056\/NEJMoa2313917","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer M","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, et al.. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025, 392:427-37. 10.1056\/NEJMoa2410027","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic V","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al.. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024, 391:109-21. 10.1056\/NEJMoa2403347","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke F","year":"2024","unstructured":"Tacke F, Horn P, Wong VW, et al.. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024, 81:492-542. 10.1016\/j.jhep.2024.04.031","journal-title":"J Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba R","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, et al.. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024, 391:299-310. 10.1056\/NEJMoa2401943","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal AJ","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, et al.. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025, 392:2089-99. 10.1056\/NEJMoa2413258","journal-title":"N Engl J Med"},{"key":"ref20","unstructured":"U.S. Food and Drug Administration. FDA approves treatment for serious liver disease known as MASH. (2025). Accessed: June 17, 2026: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1326ST","article-title":"The role of weight management in the treatment of adult obstructive sleep apnea. An official American Thoracic Society clinical practice guideline","volume":"198","author":"Hudgel DW","year":"2018","unstructured":"Hudgel DW, Patel SR, Ahasic AM, et al.. The role of weight management in the treatment of adult obstructive sleep apnea. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2018, 198:e70-87. 10.1164\/rccm.201807-1326ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra A","year":"2024","unstructured":"Malhotra A, Grunstein RR, Fietze I, et al.. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024, 391:1193-205. 10.1056\/NEJMoa2404881","journal-title":"N Engl J Med"},{"key":"ref23","unstructured":"U.S. Food and Drug Administration. FDA approves first medication for obstructive sleep apnea. (2024). Accessed: June 17, 2026: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-medication-obstructive-sleep-apnea."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure","volume":"35","author":"Green CP","year":"2000","unstructured":"Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000, 35:1245-55. 10.1016\/S0735-1097(00)00531-3","journal-title":"J Am Coll Cardiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in people with type 2 diabetes and increased cardiovascular risk in the SURPASS-4 trial: a post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink HJL","year":"2022","unstructured":"Heerspink HJL, Sattar N, Pavo I, et al.. Effects of tirzepatide versus insulin glargine on kidney outcomes in people with type 2 diabetes and increased cardiovascular risk in the SURPASS-4 trial: a post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022, 10:774-85. 10.1016\/S2213-8587(22)00243-1","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0\u2009mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial","volume":"40","author":"Blackman A","year":"2016","unstructured":"Blackman A, Foster GD, Zammit G, et al.. Effect of liraglutide 3.0\u2009mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016, 40:1310-9. 10.1038\/ijo.2016.52","journal-title":"Int J Obes (Lond)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He L","year":"2022","unstructured":"He L, Wang J, Ping F, et al.. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022, 182:513-9. 10.1001\/jamainternmed.2022.0338","journal-title":"JAMA Intern Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2024.08.033","article-title":"Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period","volume":"20","author":"Kindel TL","year":"2024","unstructured":"Kindel TL, Wang AY, Wadhwa A, et al.. Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surg Obes Relat Dis. 2024, 20:1183-6. 10.1016\/j.soard.2024.08.033","journal-title":"Surg Obes Relat Dis"},{"key":"ref29","unstructured":"WEGOVY (semaglutide) injection, for subcutaneous use. prescribing information. (2026). Accessed: June 17, 2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/215256s033lbl.pdf."},{"key":"ref30","unstructured":"ZEPBOUND (tirzepatide) injection, for subcutaneous use. prescribing information. (2026). Accessed: June 17, 2026: https:\/\/pi.lilly.com\/us\/zepbound-uspi.pdf."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1616338","article-title":"Aerobic or resistance exercise, or both, in dieting obese older adults","volume":"376","author":"Villareal DT","year":"2017","unstructured":"Villareal DT, Aguirre L, Gurney AB, et al.. Aerobic or resistance exercise, or both, in dieting obese older adults. N Engl J Med. 2017, 376:1943-55. 10.1056\/NEJMoa1616338","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.08.045","article-title":"AGA clinical practice guideline on pharmacological interventions for adults with obesity","volume":"163","author":"Grunvald E","year":"2022","unstructured":"Grunvald E, Shah R, Hernaez R, et al.. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022, 163:1198-225. 10.1053\/j.gastro.2022.08.045","journal-title":"Gastroenterology"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens PE","year":"2024","unstructured":"Stevens PE, Ahmed SB, Carrero JJ, et al.. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024, 105:S117-314. 10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial","volume":"389","author":"Jastreboff AM","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP, et al.. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023, 389:514-26. 10.1056\/NEJMoa2301972","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/508895-from-weight-loss-to-organ-specific-disease-modification-a-narrative-review-of-incretin-based-therapies-in-obesity-related-cardiometabolic-disease-chronic-kidney-disease-metabolic-dysfunction-associated-steatohepatitis-and-obstructive-sleep-apnoea","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:29:07Z","timestamp":1783344547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/508895-from-weight-loss-to-organ-specific-disease-modification-a-narrative-review-of-incretin-based-therapies-in-obesity-related-cardiometabolic-disease-chronic-kidney-disease-metabolic-dysfunction-associated-steatohepatitis-and-obstructive-sleep-apnoea"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.112135","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,6]]}}}